The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader sector now triggers questions about future yields . Generic versions are eroding exclusivity , prompting concerns that investing in companies significantly dependent to Viagra's once-dominant influence could be a problemati